Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.

@article{Lemos2005DifferentialMR,
  title={Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.},
  author={Jos{\'e} Alexandre Rodrigues de Lemos and Ciane Martins de Oliveira and Ana Carolina Costa Scerni and Alessandra Quinto Bentes and Ana Cristina Beltr{\~a}o and I{\^e} Regina G Bentes and Tereza Cristina Azevedo and Luciana Maria Cunha Maradei-Pereira},
  journal={Genetics and molecular research : GMR},
  year={2005},
  volume={4 4},
  pages={803-11}
}
Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemogenesis in CML. The aim of this observational cohort study was to discriminate and quantify BCR-ABL… CONTINUE READING